Picture Fairtec GmbH Worldwide Event Solutions 650x65px
Document › Details

Caprotec Bioanalytics GmbH. (1/26/10). "Press Release: Caprotec Bioanalytics Announces Commercial Launch of Three New caproKits for Applications in Proteomics and Drug Development". Berlin & Burlington, MA.

Organisations Organisation Caprotec Bioanalytics GmbH
  Organisation 2 Caprotec Inc.
  Group Caprotec (Group)
Products Product Marimastat caproKit
  Product 2 CCMS technology (Capture Compound Mass Spectrometry)
Persons Person Köster, Hubert (Caprotec 200805–201009 Managing Director + Univ Hamburg + Sequenom founder + CEO)
  Person 2 Jurinke, Christian (Stratec 201110 Marketing Manager at Stratec Molecular before Caprotec before Sequenom)

caprotec bioanalytics GmbH announced today the commercial launch of three new caproKits(TM), enabling the discovery, identification and characterization of proteins belonging to the groups of metallo-proteases, histon-deacetylases and GDP/GTP binding

The three new kits are the Marimastat caproKit, SAHA caproKit and GDP caproKit,
respectively and increase the number of commercially available caproKits to a total
of seven.

The company’s caproKits are based on the proprietary Capture Compound Mass
Spectrometry (CCMS) technology, a novel and direct way to investigate small
molecule - protein interactions resulting in a significant functional reduction of
proteome complexity. Capture Compounds(TM) enable direct isolation and
identification of proteins including membrane proteins out of complex biological

The new and existing caproKits target different areas of research ranging from
signal transduction (cAMP, cGMP, Stauro and the new GDP caproKit) to epigenetics
(SAH and the new SAHA caproKit), and proteases (Marimastat caproKit). Additional
caproKits for applications in these and other research areas are under development
and will be released in the coming months.

“Our new caproKits are innovative and effective tools for researchers in the field of
proteomics needing a solution for targeted reduction of sample complexity,” stated
Dr. Hubert Köster, CEO of caprotec bioanalytics. “Our most recent scientific
publications in Molecular and Cellular Proteomics and Toxicological Sciences provide
powerful testimonials for the capabilities of our CCMS technology.“

About caprotec bioanalytics GmbH

caprotec bioanalytics is headquartered in Berlin, Germany with a US subsidiary in
Burlington, MA. The company focuses on the commercialization of its proprietary
Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS
technology consists of small, tri-functional molecules called Capture
Compounds(TM). They enable a targeted isolation of proteins directly from complex
biological samples. After isolation the captured proteins are identified and
characterized by mass spectrometry or gel electrophoresis and Western blotting.
Providing a state-of-the-art platform for the isolation and analysis of proteins from
complex mixtures, the CCMS technology has enormous potential in proteomics, drug
development and the development of biomarkers. The technology is protected by a
broad patent portfolio.


Luo, Y. et al. (2009), Mol. Cell. Proteomics 8, pp. 2843-2856: The cAMP capture
compound mass spectrometry as a novel tool for targeting cAMP-binding proteins:
from protein kinase A to potassium/sodium hyperpolarization-activated cyclic
nucleotide-gated channels.

Fischer, J.J. et al. (2009), Toxicol. Sci., in press, advanced online publication
available: Capture Compound Mass Spectrometry (CCMS) Sheds Light on the
Molecular Mechanisms of Liver Toxicity of two Parkinson Drugs.

For further information please contact:

Dr. Hubert Köster, CEO, caprotec GmbH
Phone: +49 (0)30-6392-3990


Dr. Christian Jurinke, President, caprotec Inc.
Phone: (781) 685-4992

Record changed: 2016-03-19


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Caprotec Bioanalytics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top